Sorafenib is the first and only orally administered drug currently approved to treat advanced hepatocellular carcinoma (HCC). However, concerns have been raised about sorafenib therapy, including acquired drug resistance. This review provides an overview of sorafenib in the treatment of HCC on the basis of data obtained in the laboratory and in clinical studies. Three underlying mechanisms have been found to support sorafenib therapy. First, sorafenib blocks HCC cell proliferation by inhibiting BRaf and Raf1/c-Raf serine/threonine kinase phosphorylation in the mitogen activated protein kinase (MAPK) pathway. Second, sorafenib induces apoptosis by reducing elF4E phosphorylation and down-regulating Mcl-1 levels in tumor cells. Third, sorafenib prevents tumor-associated angiogenesis by inactivating vascular endothelial growth factor receptors (VEGFR-2 and VEGFR-3) and the platelet-derived growth factor receptor-β (PDGFR-β). Clinical trials have demonstrated the effectiveness and relative safety of sorafenib, and thus the drug is used in un-resectable HCC. However, many patients may develop acquired resistance to sorafenib, so their response to sorafenib is eventually lost. Sorafenib may induce autophagy, which leads to apoptosis. However, autophagy can also cause drug resistance. Many studies have combined sorafenib with other treatments in an effort to increase its effects, reduce the necessary dosage, or overcome resistance. It is urgent to study the mechanisms underlying how sorafenib interacts with cellular molecules and other drugs to increase its efficacy and reduce resistance in HCC patients.
Introduction
Liver cancer is the fifth most common cancer in the world. 1 Its mortality rate ranks third among all cancers. 1 The most common type of liver cancer is hepatocellular carcinoma (HCC), a disease often caused by Hepatitis B or C or cirrhosis. 2 In HCC, the mitogen activated protein kinase (MAPK) pathway is often constitutively active, which leads to overexpression of genes that promote cell proliferation. Apoptosis is often prevented by overproduction of the survival factor Mcl-1. Angiogenesis, mediated by the receptor tyrosine kinases in the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) families, ensures that the tumor receives adequate nutrients and oxygen.
The standard therapy for HCC is removal of the tumor by surgery. This treatment is indicated if liver function is well-preserved and there is only one tumor. 3 Five-year survival rates for these patients can range from 89% -93%. 3 Unfortunately, HCC is often detected too late for surgery to be effective. Other options include liver transplantation and percutaneous treatments. 3 However, there are limited donor livers available, and percutaneous treatments can only be used on patients with early un-resectable HCC. 3 Most patients with liver cancer are diagnosed with advanced HCC, which limits their treatment options to the oral chemotherapeutic agent, sorafenib (Nexavar). Sorafenib is indicated for HCC patients in Child-Pugh Class A and B, but it may not be safe or effective for those in Child-Pugh Class C. 4, 5 Sorafenib has been shown to increase the mean survival time by approximately three months, 6 but it usually cannot put patients into remission. In this review, we discuss the discovery, molecular mechanisms, clinical trials, resistance mechanisms, autophagy induction, and combined treatments of sorafenib.
Discovery of Sorafenib
Sorafenib is a bi-aryl urea. Its chemical name is N-(3-trifluoromethyl-4-chlorophenyl)-N′-(4-(2-methylcarbamoyl pyridin-4-yl) oxyphenyl) urea.
Sorafenib was developed by Bayer and Onyx in 1995. 7, 8 The path to development had begun in the 1980's, when oncogenes were discovered. Many oncogenes affect the growth factors, growth factor receptor kinases, or non-receptor tyrosine kinases of the MAPK pathway. Since Raf1 (also known as c-Raf) is the first member of this pathway, efforts were focused on this molecule. When overexpressed, Raf1 prolongs cell survival and can lead to many types of cancers, even in the absence of oncogenic mutations. A study conducted by Kasid et al. found that disrupting the Raf1 gene hinders the growth of human breast, ovarian, and lung tumor xenographs in athymic mice, confirming Raf as a suitable anticancer target. 9 After the scintillation proximity assay for high-throughput screening of MAPK pathway inhibitors had been developed by McDonald et al., 10 Bayer and Onyx were ready to screen molecules for Raf inhibition. They tested over 200,000 compounds, eventually finding that the promising 3-thienyl urea 1 had a Raf1 IC 50 of 17 μM. 8, 11 They were able to increase the inhibitory potency by a factor of 10 by substituting a methyl on the phenyl ring. After creating a combinatorial library of approximately 1,000 bis-aryl urea analogues, these compounds were screened against Raf1 to find an analogue with an IC 50 of only 1.1 μM. Sorafenib was discovered after several substitutions and modifications of functional groups. Not only could sorafenib inhibit Raf1, but it could also inhibit the wild-type BRaf, the oncogenic b-raf V600E kinases, VEGFRs 1, 2, and 3, PDGFR-β, fibroblast growth factor receptor 1 (FGFR1), c-Kit, Flt-3, and RET. 12, 13 
Molecular Mechanisms of Sorafenib
Sorafenib works by inhibiting several kinases in the MAPK pathway ( Figure 1A ). The Gprotein Ras is a key member of the MAPK pathway, and it helps regulate the Raf/Mek/Erk cascade. 12 Downstream from Ras is a family of Raf serine/threonine kinases. These kinases start a phosphorylation cascade that eventually leads to the transcription of genes that promote cell proliferation. 14 The Raf family is made up of ARaf, BRaf, and Raf1. Sorafenib targets Raf1 15, 16 and BRaf. 12 Liu et al. showed that 3-10 μmol/L of sorafenib inhibited Mek and Erk phosphorylation in PLC/PRF/5 HCC cells, and only 1-3 μmol/L was needed for this same effect in HepG2 HCC cells. 17 Erk phosphorylation is also inhibited by sorafenib in MDA-MB-231 human breast carcinoma cells, Mia PaCa 2 human pancreatic tumor cells, and HCT 116 and HT-29 human colon tumor cell lines, but not the NCI-H460 and A549 non-small cell lung cancer cells. 12 Erk activates Myc, a transcription factor for Cyclin D1, which may help promote cell proliferation. Sorafenib at 10 μmol/L decreases the Cyclin D1 level by inhibiting Mek/Erk in both HepG2 and PLC/PRF/5 cell lines. 17 Reduced Cyclin D1 levels leads to decreased transcription of genes that are involved in cell proliferation.
Sorafenib induces apoptosis in multiple cancer cell lines by down-regulating and inhibiting the translation of Mcl-1, a Bcl-2 family member ( Figure 1A ). 17 The pro-survivor factor Mcl-1 normally works to prevent apoptosis. It does this by inhibiting Bak, a protein that promotes apoptosis. Studies completed by Rahmani et al. demonstrated a linkage between the translational factor elF4E and Mcl-1. 18 When 1 and 10 μmol/L of sorafenib were introduced to the HepG2 and PLC/PRF/5 cell lines, they each reduced the amount of phosphorylated elF4E. 17 At 10 μmol/L and 16 hours later, Mcl-1 protein levels were also reduced. 17 The levels of elF4E phosphorylation and Mcl-1 were both not affected by the Mek inhibitor U0126 in HepG2 cells, showing that these down-regulations are independent of the Mek/Erk signaling pathway. 17 Thus, the working model suggests that sorafenib prevents elF4E phosphorylation, blocking the initiation of Mcl-1 translation. Sorafenib also caused DNA fragmentation with an EC 50 of 7.7 μmol/L in PLC/PRF/5 cells and an EC 50 of 2.4 μmol/L in HepG2 cells. 17 Sorafenib can also inhibit cancer tumor growth by targeting PDGFR-β, VEGFR-2, and VEGFR-3, three tyrosine kinases that promote angiogenesis ( Figure 1B ). In the angiogenetic pathway, these kinases activate Ras and the Raf/Mek/Erk cascade to transcribe genes that lead to angiogenesis. When VEGFR-2 and PDGF-β signaling are simultaneously inhibited, tumor vessel growth regresses due to endothelial cell apoptosis. 19 Sorafenib at 30 and 100 mg/kg was also shown to significantly (P<0.001) reduce tumor microvessel area in PLC/ PRF/5 xenografts in CB17 severe combined immunodeficient mice. 17 By decreasing angiogenesis, sorafenib helps cut off the blood supply to the tumor and starve its cells.
Clinical Studies
In 2005, Phase I clinical studies were undertaken to establish the pharmacokinetics and safety of sorafenib. 20 In the dose-escalation study, 69 patients with advanced, refractory solid tumors were administered 50-800mg of sorafenib once or twice daily. Nine of these patients had HCC. The sorafenib dosage increased until the occurrence of "unacceptable toxicity, withdrawn consent, disease progression, tumor progression, or death."
The study concluded that oral sorafenib appeared to provide some clinical benefits, and it was generally well-tolerated. Flow cytometry showed that Erk phosphorylation was significantly decreased at doses above 200 mg (P<0.01). Out of the 45 patients eligible for efficacy testing, 1 patient showed a partial response, 25 patients had stable disease, 18 patients had progressive disease, and 1 patient's tumor response could not be evaluated. The most common side-effect was diarrhea (experienced by 55% of those treated), followed by hand-foot syndrome (23%), and rashes (26%). The maximum tolerated dose (MTD) was 500 mg mid continuous; many participants with doses higher than this dropped out due to intolerable toxicity. A dosage of 400 mg bid continuous was recommended for future studies.
The Phase II trials in 2006 measured the efficacy, toxicity, pharmacokinetics, and biomarkers of sorafenib in advanced HCC patients (clinicaltrials.gov, NCT00044512). 21 In this study, 137 patients with inoperable HCC and no prior systemic treatment were given continuous, 400 mg bid oral sorafenib in 4 week cycles. Of the 57 patients assessable for efficacy, 3 patients had a partial response, 8 had a minor response, and 46 had stable disease for at least 16 weeks. The modest efficacy of sorafenib suggested its use in combination with other anticancer drugs.
In 2008, Phase III trials were conducted by the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) Investigators Study Group in a double-blind, placebo controlled manner (clinicaltrials.gov, NCT00105443). 6 The study administered 400 mg of sorafenib or a placebo bid to 602 patients with advanced HCC and no prior systemic treatment. All patients were required to have well-conserved liver function (Child-Pugh class A) to ensure that deaths caused by advanced liver disease did not hide the activity of sorafenib.
Sorafenib increased the median survival time by approximately 3 months (the median for sorafenib was 10.7 months, while the median for the placebo group was 7.9 months). The median time to symptomatic progression was approximately equal in both groups. However, the median time to radiologic progression was 5.5 months in the sorafenib group and only 2.8 months in the placebo group (P<0.001). Only 2% of patients in the sorafenib group had a partial response, as defined by a 30% decrease in the sum of tumor diameters. The overwhelming majority of sorafenib patients (71%) had stable disease. In the placebo group, 1% of patients had a partial response and 67% had stable disease. The sorafenib group was also more likely to experience diarrhea, weight loss, hand-foot syndrome, and hypophosphatemia than those in the placebo group. The SHARP trials concluded that sorafenib was effective in increasing survival time, but the data shows that tumor response rates were very low.
In the same year, Bruix et al. analyzed the data from the SHARP trial to determine if patients with macroscopic vascular invasion (MVI) or extrahepatic spread (EHS) responded differently to sorafenib compared to those without these complications. 22 They found that all patients survived longer overall and had a greater time to progression if they were given sorafenib, regardless if they had MVI or EHS.
In 2012, another study that drew upon the SHARP trials revealed that survival in patients with advanced HCC could be predicted by the concentrations of angiopoietin 2 and VEGF, both angiogenesis biomarkers. 23 However, none of the plasma biomarkers could predict response to sorafenib.
In order to confirm the results of the SHARP trials, a second phase III study was conducted in the Asia-Pacific Region (clinicaltrials.gov, NCT00492752). 24 This region contains the most cases of HCC because it has a high prevalence of chronic hepatitis B infection. The trials randomly divided 271 patients with advanced HCC and no previous systematic therapy into two groups: sorafenib (226 patients) and placebo (76 patients). The patients were administered oral sorafenib or a placebo two times a day in six week cycles.
The median survival of patients was 6.5 months in those taking sorafenib but only 4.2 months for those with the placebo. In addition, the time to progression was twice as long in the sorafenib patients (2.8 months) as in the placebo patients (1.4 months) . Thus, the AsiaPacific trials confirmed the efficacy of sorafenib found in the SHARP trials.
Additionally, the Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with SorafeNib (GIDEON) study has been undertaken to determine sorafenib's safety and efficacy in different subgroups (clinical trials.gov, NCT00812175). 25 This ongoing and global study follows 3,000 patients from over 40 countries who are taking sorafenib in practice settings for unresectable HCC. The first results of this study indicate that hepatologists and gastroenterologists tend to treat patients with higher doses of sorafenib over a longer period of time than medical oncologists. 26 The study will follow its patients for approximately 5 years in order to generate a large and robust database that can analyze characteristics of patients with HCC, the disease itself, and treatment patterns.
Resistance to Sorafenib
Although sorafenib seems to be effective in prolonging median survival time with limited side effects in HCC patients, it may cause resistance in many patients. Studies on sorafenibresistant Huh7 cells have revealed the prominent role that the P13K/Akt pathway plays in producing resistance to sorafenib. 27 The P13K/Akt pathway is involved with apoptosis: when it is active, apoptosis is reduced and cell proliferation increases. In this pathway, prosurvival factors bind to a receptor tyrosine kinase, which activates the kinase P13K. Activated P13K starts a cascade that leads to phosphorylated Akt, which inhibits apoptosis.
Wild type Huh7, Hep3B, and PLC5 cells all undergo apoptosis when exposed to increasing amounts of sorafenib. Chen et al. produced two lines of Sorafenib-resistant HCC cells (Huh7-R1 and Huh7-R2) by exposing Huh7 cells to sorafenib for a long time and gradually increasing the dosage. 27 These cells showed resistance to sorafenib at the highest achievable clinical concentration (10μM). They also demonstrated upregulation of Akt, a characteristic common in many human cancer types. HepG2 and Sk-Hep1 resistant cells demonstrated this upregulation as well. Sensitivity to sorafenib-induced apoptosis can be restored when siRNA is used to knockdown Akt in HCC cells or the Akt inhibitor MK-2206 and sorafenib are both added to the cells.
Increased expression of epidermal growth factor receptor and HER-3 may also limit HCC cell response to sorafenib. 28 When sorafenib was combined with gefitinib, a drug that inhibits EGFR and HER-3 phosphorylation, the drugs inhibited tumor growth more effectively together (~65% inhibition) than separately (~30% inhibition) in PLC/PRF5 subcutaneous xenografts. The combination also reduced cell viability in HepG2, Hep3B, PLC/PRF5, Huh6, and Huh7 cells in vitro better than each agent alone.
Epithelial-mesenchymal transition (EMT) may also play a role in sorafenib resistance. A study completed by Malenstein et al. demonstrated that HepG2 cells resistant to sorafenib transitioned from epithelial to mesenchymal cells. 29 HepG2 cells became resistant to sorafenib after being exposed to 6μM and 8μM doses. They became spindle-shaped, lost Ecadherin, and gained a high expression of vimentin, which enabled them to become more invasive. These sorafenib-resistant HepG2 cells were also resistant to the mTOR inhibitor everolimus, but not LY294002, a PI3K-inhibitor. Resistant HepG2 and WRL-68 cell lines greatly increased in proliferation and metabolic activity after sorafenib was withdrawn.
Cells resistant to sorafenib may undergo EMT, but several studies have shown that sorafenib actually inhibits this process in most primary hepatocytes and HCC cells. When mouse primary hepatocytes were exposed to sorafenib, transforming growth factor β (TGF-β) signaling was decreased, and this diminished EMT. 30 In another study, Nagai et al. introduced hepatocyte growth factor (HGF) to induce EMT morphology and migration in HepG2 and Huh7 cells. 31 These cells showed increased SNAI1 and N-cadherin expression and decreased E-cadherin expression, all indicators of EMT. Sorafenib inhibited these changes and even stopped the HGF-mediated cell migration. Thus, sorafenib can restrain EMT transition in most HCC cells, but cells resistant to sorafenib continue to transition.
Sorafenib and Autophagy
Autophagy is a process by which cells recycle material by enclosing an organelle within a vesicle and fusing it with a lysosome to degrade it. This mechanism may promote cancer growth because it enables the cells to survive nutrient deprivation. A study completed by Shimizu et al. discovered that sorafenib increases autophagy in Huh7, HLF, and PLC/PRF/5 cells, which leads to resistance. 32 Chloroquine, an inhibitor of autophagic flux, can be added in combination with sorafenib to significantly increase the suppression of tumor growth in vivo. 32 In another study, markers of autophagy, including LC3-11, Atg5, and autophagosomes, increased when cells were exposed to sorafenib. 33 This autophagy was induced by endoplasmic reticulum stress. When autophagy was inhibited by 3-MA, choloroquine, or Atg5 siRNA knockdown, sorafenib-induced cell death increased. However, another study has shown that excess autophagy can promote apoptosis and decrease tumor size. When sorafenib was combined with pemetrexed, a folate anti-metabolite that stimulates autophagy, the treatment increased autophagy and cell death in vitro and suppressed tumor growth in vivo. 34 The interaction was not merely additive, but synergistic. Thus, autophagy can either enable cell survival or promote cell death, and further investigations may elucidate the different circumstances under which each occurs.
Sorafenib in Combination with Other Therapies
Many recent studies have tested the efficacy of sorafenib in combination with another therapy to investigate if the effects of the multikinase inhibitor can be improved. Since overactive epidermal growth factor receptor (EGFR) expression potentially leads to sorafenib resistance, 35 Yang et al. tested sorafenib with CH12, a monoclonal antibody against EGFRvIII in Huh-7 cells, SMMC-7721 cells, and Huh-7 cells overexpressing EGFRvIII (Huh-7-EGFRvIII) in vitro and in vivo. 36 They found that the combination was indeed more effective than sorafenib alone in Huh-7-EGFRvIII and SMMC-7721 cells. The MEK/ERK, phosphoinositide 3-kinase/AKT, and STAT3 pathways all showed increased inhibition with the addition of CH12.
Since Erlotinib is a drug that also inhibits EGFR, Sieghart et al. endeavored to discover if it too could be combined with sorafenib to produce additive effects. 37 However, when used in an orthotopic rat model of hepatocellular carcinoma, erlotinib did not significantly change the tumor cell viability, and the combination did not produce any further effects.
Another study conducted by Wang et al. combined sorafenib with Interferon-alpha (IFN-α), a type I interferon cytokine that activates the JAK-STAT pathway. 38 IFN-α has been commonly used in renal cell carcinoma, melanoma, and chronic myelogenous leukemia because it inhibits angiogenesis and tumor cell proliferation. The combination produced a synergistic effect: it decreased HCC cell viability, blocked the progression of the cell cycle, and promoted apoptosis in vitro. In vivo, the combination also inhibited tumor growth and induced apoptosis.
The combination of sorafenib and panobinostat is another promising treatment for HCC. Panobinostat is a drug that inhibits histone deacetylases (HDAC), which are frequently dysregulated in cancer. When combined with sorafenib, panobinostat decreased cell viability and proliferation and increased apoptosis and autophagy in vitro. 39 HCC xenografts also had decreased tumor volumes and lived longer when treated with the combination.
In a Phase II clinical trial, sorafenib was combined with 5-flurouracil (5-FU) in patients with advanced HCC (clinicaltrials.gov, NCT00619541). 40 5-FU has cytotoxic effects in HCC cells and xenograft models, and it is commonly used to treat gastrointestinal cancers. Thirtynine patients were given sorafenib at 400 mg bid and an infusion of 5-FU at 200 mg/sqm/ daily from days 1-14 every 3 weeks. The median time to progression was 8 months, and the median survival time was 13.7 months. The combination was deemed safe, with promising efficacy.
Transarterial chemoembolization (TACE) is a common treatment for moderate HCC, and clinical trials aimed to discover if it could be safely combined with sorafenib to produce better outcomes. TACE can sometimes upregulate VEGF, which can increase HCC growth, invasion, and metastasis. 41 In a Phase II trial, fifty patients with Barcelona Clinic Liver Cancer stage B or C were treated with sorafenib (median dose: 68.7% of 800 mg daily) three days after TACE treatment (clinicaltrials.gov, NCT00919009). 41 The overall median time to progression was 7.1 months, and 52% of patients survived at least 6 months. The concurrent treatment was deemed safe, and the trial promised efficacy.
A Phase III study analyzed the efficacy of sorafenib when given to Japanese and Korean patients who had already positively responded to TACE treatment. 42 Patients were given either 400mg of sorafenib bid or a placebo, and most of the patients began the treatment more than nine months after TACE. Patients taking sorafenib had a median time to progression of 5.4 months, while those taking the placebo progressed in 3.7 months. The study concluded that sorafenib did not significantly increase the time to progression for patients who had already reaped benefits from TACE. However, low doses of sorafenib and the extended time between sorafenib and TACE treatment may have contributed to this result.
Conclusions
Sorafenib remains the standard drug treatment for advanced HCC. It targets the MAPK pathway, Mcl-1, and angiogenic tyrosine receptors in order to inhibit cell proliferation, induce apoptosis, and block angiogenesis, respectively. Clinical studies have confirmed the efficacy of sorafenib, but the drug does have several side effects and patients quickly develop resistance to it. Understanding how sorafenib interacts with the autophagic process and other treatments may be essential to improve its efficacy. It is important to investigate sorafenib resistance and the effects it has on other molecules in order to improve the current liver cancer treatment. Molecular mechanisms of sorafenib. (A) Sorafenib inhibits tumor cell proliferation and promotes apoptosis. In HCC cells, sorafenib inhibits BRaf and Raf1, two protein kinases involved in the MAPK pathway to cell proliferation. These kinases can no longer activate Mek and subsequently Erk and Myc. Myc is a transcription factor which helps transcribe the cyclin D1 gene. Reduced levels of cyclin D1 are available to promote the transcription of cell proliferation genes, and thus cell proliferation slows. Sorafenib also helps promote apoptosis by inhibiting the phosphorylation of elF4E, the translation initiation factor for Mcl-1. Because reduced levels of Mcl-1 are being translated, there is less inhibition of Bak, a protein that promotes apoptosis. Thus, apoptosis is increased. (B) Sorafenib reduces tumor angiogenesis. It inhibits the tyrosine receptor kinases PDGFR-β, VEGFR-2, and VEGFR-3 in endothelial cells. These receptors can no longer activate Ras. Ras normally activates the Raf family, Mek, Erk, and finally the transcription of genes that promote angiogenesis.
Thus, tumor angiogenesis is reduced, and the tumor receives less of the oxygen and nutrients it needs to survive.
